[Synergism between cyclosporin and gangliosides in anti-rejection therapy. Experimental in vivo model].
In vivo gangliosides (GS) bring about inhibitory effects on the immune response which is attributable to a weakening of the interaction between interleukin-2 (IL-2) and its receptor. In a previous paper we showed that the GS are capable of bringing about in vitro the immunosuppressive power of cyclosporin A CyA2 in this paper we have tried to associate gangliosides (GS) and low dose of CyA in the grafting of rat allogen cutis in order to have in this way in vivo a confirmation of the results previously obtained in vitro. Cutaneous strips taken from Lewis rats were grafted into Sprague Dawley rats and treated for 21 days with intraperitoneal administration of GS, of Cya, and a mixture of the two. The rats were not treated and the rats treated with GS and with CyA separately rejected the graft of the cutis. On the other hand, the use of an association of Gs and CyA brought about a successful graft in 8 rats out of 10. Splenic cells extracted 21 days after the graft from rats treated with GS and with CyA separately were stimulated in vitro with Packweed mitogen (PWM); on the contrary the cells extracted from rats treated with a combination of the two drugs did not react to the stimulation with PWM. Our results show that the GS brings about in vivo the immunosuppressive effects of low doses of CyA.
Filingeri
V
V
Clinica Chirurgica, Università degli Studi di Roma, Tor Vergata.
Rosati
R
R
Sconocchia
G
G
Pisani
A
A
Vennarecci
G
G
Anselmo
A
A
Pepe
N
N
Barletta
N
N
Casciani
C U
CU
D000818:Animals; D002455:Cell Division / Q000187:drug effects; D016572:Cyclosporine / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D005732:Gangliosides / Q000627:therapeutic use*; D006084:Graft Rejection / Q000188:drug therapy*; D051381:Rats; D011917:Rats, Inbred Lew; D017207:Rats, Sprague-Dawley; D013154:Spleen / Q000166:cytology / Q000187:drug effects
D005732:Gangliosides; D016572:Cyclosporine
Sinergismo tra ciclosporina e gangliosidi nella terapia antirigetto. Modello sperimentale in vivo.